全文获取类型
收费全文 | 2377篇 |
免费 | 102篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 56篇 |
妇产科学 | 33篇 |
基础医学 | 300篇 |
口腔科学 | 62篇 |
临床医学 | 220篇 |
内科学 | 688篇 |
皮肤病学 | 22篇 |
神经病学 | 211篇 |
特种医学 | 26篇 |
外科学 | 379篇 |
综合类 | 6篇 |
预防医学 | 129篇 |
眼科学 | 40篇 |
药学 | 125篇 |
肿瘤学 | 169篇 |
出版年
2022年 | 32篇 |
2021年 | 52篇 |
2020年 | 22篇 |
2019年 | 28篇 |
2018年 | 43篇 |
2017年 | 37篇 |
2016年 | 44篇 |
2015年 | 44篇 |
2014年 | 60篇 |
2013年 | 75篇 |
2012年 | 123篇 |
2011年 | 103篇 |
2010年 | 71篇 |
2009年 | 65篇 |
2008年 | 140篇 |
2007年 | 112篇 |
2006年 | 112篇 |
2005年 | 124篇 |
2004年 | 96篇 |
2003年 | 123篇 |
2002年 | 127篇 |
2001年 | 78篇 |
2000年 | 74篇 |
1999年 | 63篇 |
1998年 | 22篇 |
1997年 | 23篇 |
1996年 | 26篇 |
1995年 | 14篇 |
1994年 | 12篇 |
1992年 | 25篇 |
1991年 | 29篇 |
1990年 | 38篇 |
1989年 | 29篇 |
1988年 | 27篇 |
1987年 | 29篇 |
1986年 | 23篇 |
1985年 | 17篇 |
1984年 | 14篇 |
1979年 | 16篇 |
1976年 | 16篇 |
1975年 | 25篇 |
1974年 | 14篇 |
1973年 | 17篇 |
1972年 | 20篇 |
1971年 | 19篇 |
1970年 | 31篇 |
1969年 | 16篇 |
1968年 | 18篇 |
1967年 | 25篇 |
1966年 | 19篇 |
排序方式: 共有2483条查询结果,搜索用时 15 毫秒
61.
Toru Kitazawa MD Hiroaki Seino MD Hiroshi Ohashi MD Takeshi Inazawa MD Masahiro Inoue MD Masumi Ai MD Midori Fujishiro MD Hisamoto Kuroda MD Masayo Yamada MD Motonobu Anai MD Hisamitsu Ishihara MD 《Diabetes, obesity & metabolism》2020,22(9):1659-1663
Metformin plus a dipeptidyl peptidase-4 inhibitor (DPP-4i) is the most common therapy for Japanese patients with type 2 diabetes. This 24-week, multicentre, open-label, parallel-group trial randomized patients on dual therapy to add-on tofogliflozin (20 mg/day, n = 33) or glimepiride (0.5 mg/day, n = 31). The primary outcome was change in body fat percentage. The secondary outcomes included changes in HbA1c, fat mass, fat-free mass, liver function variables and uric acid. Tofogliflozin and glimepiride reduced HbA1c to a similar extent. Body fat percentage did not change from baseline in either group. Fat mass was reduced by tofogliflozin but was increased by glimepiride (by −2.0 ± 1.7 kg and +1.6 ± 1.6 kg, P = .002). Fat-free mass was also reduced by tofogliflozin and increased by glimepiride (by −1.3 ± 1.3 kg and +0.9 ± 2.0 kg, P < .001). Alanine aminotransferase and uric acid levels were reduced by tofogliflozin (P = .006 and P < .001, respectively). These data provide novel information useful for selecting the third oral agent for patients whose diabetes is inadequately controlled with metformin plus DPP-4i dual therapy. 相似文献
62.
63.
64.
65.
K Kageyama S Yamagata K Akimoto A Sugiyama S Murasawa T Suda 《Molecular and cellular endocrinology》2012,362(1-2):221-226
Corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) are the two major regulatory peptides in the hypothalamic-pituitary-adrenal (HPA) axis. Glucagon-like peptide-1 (GLP-1), an important regulator of metabolism or energy homeostasis, is implicated in the regulation of the HPA axis in response to stress and may act directly on CRF and AVP neurons. To elucidate the direct regulation of CRF and AVP genes by GLP-1 in the hypothalamus, we examined the effect of GLP-1 in hypothalamic 4B cells, which show the characteristics of hypothalamic paraventricular nucleus neurons. The mRNA of GLP-1 receptor was detected in 4B cells by RT-PCR. GLP-1 significantly stimulated both CRF and AVP mRNA levels. Cells were transfected with CRF or AVP promoter to examine the activity of each promoter. GLP-1 directly stimulated the activities of both CRF and AVP promoters in hypothalamic 4B cells. Basal promoter activities of both CRF and AVP were increased in higher glucose medium. In addition, CRF and AVP promoter activities were increased by GLP-1 in standard or low glucose medium but not in higher glucose medium. An equimolar concentration of metabolically inactive l-glucose failed to mimic the effect of d-glucose, indicating that the event was caused by changes in glucose levels and not by hyperosmolality. Together, these data suggest that GLP-1 would contribute to stress responses through activation of CRF and AVP genes in the hypothalamic cells. Hyperglycemia may be one of the stressors enhancing the syntheses of CRF and AVP in the hypothalamus. 相似文献
66.
67.
Kojima T Kaneko A Hirano Y Ishikawa H Miyake H Oguchi T Takagi H Yabe Y Kato T Ito T Terabe K Fukaya N Kanayama Y Shioura T Funahashi K Hayashi M Kato D Matsubara H Fujibayashi T Kojima M Ishiguro N;TBC 《Modern rheumatology / the Japan Rheumatism Association》2012,22(3):339-345
Biologic agents have proven to be effective against rheumatoid arthritis (RA) in clinical trials and post-marketing surveillance (PMS) studies. However, limited follow-up periods and strict criteria for recruitment might lead to an underestimation of adverse events. To document the long-term course of patients with RA treated with biologics in clinical settings, we established the Tsurumai Biologics Communication Registry (TBCR). First, we retrospectively collected data of patients registered for any biologic PMS study or clinical trial at participating institutes. Thus far, thirteen institutes have joined the registry and 860 patients have been identified. Comparing baseline characteristics by age and initiation year of biologics, young patients had significantly less joint damage and dysfunction and a higher dose of concomitant methotrexate (MTX) compared to older patients. Older age and functional class were significantly related to the incidence of adverse events that resulted in discontinuation of the 1st biologic treatment. The TBCR is in its initial stages, and information on all patients newly starting biologic therapy at participating institutes is being collected prospectively. Differences in baseline characteristics by age and initiation year of biologics need to be carefully evaluated in order to report on drug-related survival and long-term prognosis, using follow-up data in the near future. 相似文献
68.
69.
Yukifumi Monden Masato MoriMari Kuwajima Tamako GotoTakanori Yamagata Mariko Y. Momoi 《Brain & development》2013
We report the case of a boy with myoclonic epilepsy with ragged-red fibers (MERRF) who had astatic seizures since 2 years of age and later developed ataxia, absence seizures, and myoclonus. Almost homoplasmic A8344G mutation of mitochondrial DNA (m.8344A>G mutation) was detected in lymphocytes. He developed late-onset Leigh syndrome (LS) when he contracted pneumonia at 6 years. He developed bulbar palsy and deep coma. MRI demonstrated lesions in the brainstem, basal ganglia, and cerebral cortex. Three similar cases have been reported; two carried the almost-homoplasmic m.8344A>G mutation in muscle tissue. These suggested that almost homoplastic m.8344A>G mutation developed clinical phenotype of MERRF in the early stage and late-onset Leigh syndrome in the late course of the disease. 相似文献